Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor T cells for various cancers and other indications
WEXFORD, Pa., May 10, 2023... | June 15, 2023

Related Keywords

,Jon Nugent ,Jason Lohmueller ,Dave Mehalick ,Karolinska Institutet ,David Schemelia ,University Of Pittsburgh ,Drug Administration ,Prnewswire Coeptis Therapeutics Holdings Inc ,Nature Communications ,Coeptis Therapeutics Inc ,Coeptis Pharmaceuticals Inc ,Coeptis Therapeutics Holdings Inc ,Securities Exchange ,Holdings Inc ,Division Of Surgical Oncology Research ,Exchange Commission ,Nasdaq ,Therapeutics Holdings ,Assistant Professor ,Surgical Oncology Research ,Coeptis Therapeutics ,Coeptis Therapeutics Holdings ,Coeptis Pharmaceuticals ,Deverra Therapeutics ,Securities Act ,Securities Exchange Act ,Nasdaq Global Market ,